News round-up for 8-12 May by DDW Digital Content Editor Diana Spencer.
Inspired by the relaunch of PerkinElmer’s Life Science and Diagnostics business this week as Revvity, my top five news story this week all relate to new drug discovery business developments. See below for the latest updates from Tay Therapeutics, Cytiva, Gate Neurosciences, Bayer and Bicycle Therapeutics.
The top stories:
Tay licenses oral BET inhibitor to VYNE Therapeutics
UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2.
Cytiva and Pall Life Sciences complete integration
Cytiva and the life sciences business of Pall Corporation have completed their integration and are now united as one business under the Cytiva brand.
PerkinElmer’s Life Science and Diagnostics business becomes Revvity
PerkinElmer’s Life Science and Diagnostics business has revealed its new name and branding. Revvity has now officially launched as a science-based solutions company.
Gate Neurosciences expands research operations
Gate Neurosciences has increased its R&D capabilities with new expanded research operations and lab facilities in Evanston, Illinois.
Bayer and Bicycle collaborate on bicyclic peptides
Bayer and Bicycle Therapeutics have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialise Bicycle radioconjugates for multiple oncology targets.
